Protect Gains in This Period of Uncertainty<br />By Rev Shark<br />RealMoney.com Contributor<br />5/4/2010 8:28 AM EDT<br /><br /> Always remember that the most important thing in a good marriage is not happiness, but stability.<br /> -- Juvenal Urbino, in Gabriel Garcia Marquez's Love in the Time of Cholera <br /><br />The pattern of alternating days of strength and weakness is continuing this morning. After a strong day yesterday, all overseas markets are in the red as concerns linger over the European sovereign debt issue. There are reports that the 110-billion-euro bailout of Greece won't be enough to cover all of the country's needs. Worries are also growing over which country will be the next to need a bailout; Spain is on the brink and is a much larger economy than Greece.<br /><br />Asia is seeing worries that the Chinese economy remains overheated and that steps will be taken to cool things off. The Reserve Bank of Australia raised rates for the sixth time since October in order to cool inflationary pressure caused by Chinese demand for natural resources.<br /><br />As these concerns have bubbled up, U.S. indices have seen a sharp increase in volatility over the past week. We have had two sharp dips and two sharp bounces and are set for a weak open today. The streak of uninterrupted days of gains has clearly been broken over the past week.<br /><br />But the bulls remain unimpressed by recent signs of a change in market character and are confident that we will continue on a relentless trajectory higher. Every dip in this market has been a buying opportunity for over a year, so why should anything change at this point? The negatives will soon be forgotten once again -- if you aren't buying weakness, then you haven't learned a thing about this market.<br /><br />The bears, who are exhausted as they keep hoping and praying for some sort of top, aren't particularly convincing, once again telling us that this time it is different and we really are going to see a market turn. We have been hearing predictions of a market top for so long it is hard to take the bears very seriously, regardless of how good their arguments may be. They will eventually be right and we'll have some sustained downside, but the bears themselves will probably be very surprised when it does happen.<br /><br />As I commented in my closing post yesterday, the increased volatility in this market over the past week is a sign the uncertainty is increasing. This uncertainty raises the chances that the market is ready for a rest, but if you're looking for a total collapse, it's unlikely to occur.<br /><br />There are cracks forming in the uptrend, and a high level of defense is warranted. We've yet to see whether this choppiness morphs into a more severe correction, but there are enough warnings signs already that a cautious stance is prudent. Nothing is more unproductive in investing and trading than giving back gains. Stay focused on keeping your portfolio as close as possible to its highs. If you can avoid having to recoup losses, you will outperform. <br />-----------------------------<br />Briefing.com:<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: NTRI +15.7%, PWAV +13.4% (also upgraded to Buy from Hold at Jefferies, upgraded to Buy from Neutral at Merriman), IPXL +12.5%, SNCR +9.9% (light volume), ANN +6.8%, IVAC +5.4%, PSEM +5.1%, LLEN +4.8%, CTSH +4.0%, MCK +4.0%, PFE +2.2%, CGNX +1.4%, MA +1.0%.<br /><br />M&A news: LIHR +5.9% (Lihir Gold and Newcrest to merge), IDC +0.7% (Interactive Data to be acquired by Silver Lake and Warburg Pincus for $33.86/share in cash).<br /><br />Select metals/mining stocks trading higher: RTP +4.2%, GOLD +2.0%, .<br /><br />Other news: MSON +31.0% (HIFU receives unanimous approval to continue the clinical investigation of high intensity focused ultrasound for treatment of prostate cancer ), EPCT +5.2% (earns $2.0 mln milestone payment from Meda AB for the first commercial shipment of Ceplene to a major country in the European Union), SPRD +4.9% (still checking), SLXP +4.7% (XIFAXAN 550 mg (rifaximin) demonstrated acute and sustained relief of non-constipation irritable bowel syndrome symptoms; data from target 1&2 presented at Digestive Disease Week), ACUR +3.9% (King Pharms and ACUR Announce Plans to Submit an NDA for Acurox Tablets Without Niacin), CNXT +2.2% (retires $106.7 mln of 4% convertible subordinated notes due 2026), FRX +1.4% (Ironwood and Forest present positive linaclotide results from two pivotal phase 3 trials in patients with chronic constipation), SNN +0.9% (light volume; New data reinforces the proven safety and effectiveness of the BIRMINGHAM HIP Resurfacing System).<br /><br />Analyst comments: SNV +2.1% (upgrded to Buy at Citigroup).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: LF -15.7%, TNL -11.2%, RDN -10.8%, SHOO -7.5%, N -7.3% (light volume), ALVR -7.3%, EMR -6.3%, BZH -6.0%, HOLX -5.6% (also downgraded to Hold at Brean Murray, downgraded to Sector Perform from Outperform at RBC Capital), SGMO -5.4% (light volume), PBI -5.1%, GLRE -3.9% (light volume), BOFL -3.8%, UBS -3.0%, GVA -2.5%, TXRH -2.5%, BZ -2.4% (light volume), VVUS -2.1%, NLY -2.1%, SFSF -2.1% (also announced it will acquire CubeTree for $20 mln in Success Factors stock), VOLC -1.6%, RAX -1.3%.<br /><br />Select financial related names showing weakness: CS -7.4% (trading ex dividend), LYG -5.8%, ING -5.4%, NBG -5.0%, STD -5.0%, BBVA -4.1%, RBS -4.0%, BCS -3.2%, UBS -2.8%, DB -2.8%, HBC -2.0%, BAC -0.9%, C -0.9%, . Select mortgage/insurer related names lower following RDN reuslts: ABK -7.8%, PMI -4.4%, MTG -3.8%, MBI -3.0%<br /><br />Select telecom names trading lower: PT -2.4%, FTE -2.0%, VOD -2.1%, TEF -2.0%, DT -2.0%.<br /><br />Select oil/gas related names showing weakness: RDS.A -2.5%, TOT -2.4%, E -2.3%, PBR -1.2%.<br /><br />Other news: PEI -6.6% (commenced a public offering of 8 mln shares of common stock), QCOR -6.3% (co held conference call to discuss the results of the FDA Panel meeting last night), FSS -4.7% (announced it will offer ~$75 mln of common stock), GHL -3.2% (will sell 3 mln shares of common stock in an underwritten agreement).<br /><br />Analyst comments: TRLG -4.9% (downgraded to Hold at Lazard), KDN -4.1% (downgraded to Hold from Buy at KeyBanc), SMG -2.2% (downgraded to Hold from Buy at Jefferies), DRE -1.4% (downgraded to Underperform from Neutral at RW Baird), CLX -1.1% (downgraded to Hold from Buy at Jefferies).